281 related articles for article (PubMed ID: 29741788)
1. Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood.
Rasmussen LJH; Moffitt TE; Eugen-Olsen J; Belsky DW; Danese A; Harrington H; Houts RM; Poulton R; Sugden K; Williams B; Caspi A
J Child Psychol Psychiatry; 2019 Feb; 60(2):199-208. PubMed ID: 29741788
[TBL] [Abstract][Full Text] [Related]
2. Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People.
Rasmussen LJH; Moffitt TE; Arseneault L; Danese A; Eugen-Olsen J; Fisher HL; Harrington H; Houts R; Matthews T; Sugden K; Williams B; Caspi A
JAMA Pediatr; 2020 Jan; 174(1):38-47. PubMed ID: 31682707
[TBL] [Abstract][Full Text] [Related]
3. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging.
Rasmussen LJH; Caspi A; Ambler A; Danese A; Elliott M; Eugen-Olsen J; Hariri AR; Harrington H; Houts R; Poulton R; Ramrakha S; Sugden K; Williams B; Moffitt TE
J Gerontol A Biol Sci Med Sci; 2021 Jan; 76(2):318-327. PubMed ID: 32766674
[TBL] [Abstract][Full Text] [Related]
4. Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor).
Bourassa KJ; Rasmussen LJH; Danese A; Eugen-Olsen J; Harrington H; Houts R; Poulton R; Ramrakha S; Sugden K; Williams B; Moffitt TE; Caspi A
Brain Behav Immun; 2021 Oct; 97():79-88. PubMed ID: 34224821
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children.
Kosecik M; Dervisoglu P; Koroglu M; Isguven P; Elmas B; Demiray T; Altindis M
Int J Cardiol; 2017 Feb; 228():158-161. PubMed ID: 27865178
[TBL] [Abstract][Full Text] [Related]
6. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
8. Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood.
Matthews T; Rasmussen LJH; Ambler A; Danese A; Eugen-Olsen J; Fancourt D; Fisher HL; Iversen KK; Schultz M; Sugden K; Williams B; Caspi A; Moffitt TE
Brain Behav Immun; 2024 Jan; 115():727-736. PubMed ID: 37992788
[TBL] [Abstract][Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
Rasmussen LJH; Petersen JEV; Eugen-Olsen J
Front Immunol; 2021; 12():780641. PubMed ID: 34925360
[TBL] [Abstract][Full Text] [Related]
10. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
[TBL] [Abstract][Full Text] [Related]
11. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
Gumus A; Altintas N; Cinarka H; Kirbas A; Hazıroglu M; Karatas M; Sahin U
Int J Chron Obstruct Pulmon Dis; 2015; 10():357-65. PubMed ID: 25709430
[TBL] [Abstract][Full Text] [Related]
13. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity.
Can U; Buyukinan M; Yerlikaya FH
Indian J Med Res; 2017 Mar; 145(3):327-333. PubMed ID: 28749394
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
16. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
[TBL] [Abstract][Full Text] [Related]
18. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.
Alstrup M; Meyer J; Schultz M; Rasmussen LJH; Rasmussen LS; Køber L; Forberg JL; Eugen-Olsen J; Iversen K
World J Surg; 2019 Mar; 43(3):780-790. PubMed ID: 30390135
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
